Patents by Inventor Emmanuel G. Cormier

Emmanuel G. Cormier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Novel sequences encoding hepatitis C virus glycoproteins
    Publication number: 20080311150
    Abstract: The present invention concerns a modified nucleic acid molecule comprising a nucleotide sequence coding for a full length hepatitis C virus (HCV) glycoprotein selected from the group consisting of E1 glycoprotein and E1/E2 glycoprotein heterodimer, this molecule having at least one nucleotide alteration, wherein, due to this alteration, at least one RNA splice site selected from the group consisting of RNA splice acceptor and RNA splice donor sites is eliminated from the coding sequence. The invention is also directed to methods for expressing on the surface of a cell and a pseudovirion an HCV glycoprotein, wherein the majority of the glycoprotein is full length. The invention further provides a cell and a pseudovirion expressing such glycoprotein. The invention still further provides a method for determining whether an agent inhibits HCV fusion with and entry into a target cell. The invention also provides an agent that inhibits HCV fusion with and entry into a target cell.
    Type: Application
    Filed: March 28, 2008
    Publication date: December 18, 2008
    Inventors: Julie Dumonceaux, Emmanuel G. Cormier, Jason P. Gardner, Tatjana Dragic
  • Sequences encoding hepatitis C virus glycoproteins
    Patent number: 7361503
    Abstract: The present invention concerns a modified nucleic acid molecule comprising a nucleotide sequence coding for a full length hepatitis C virus (HCV) glycoprotein selected from the group consisting of E1 glycoprotein and E1/E2 glycoprotein heterodimer, this molecule having at least one nucleotide alteration, wherein, due to this alteration, at least one RNA splice site selected from the group consisting of RNA splice acceptor and RNA splice donor sites is eliminated from the coding sequence. The invention is also directed to methods for expressing on the surface of a cell and a pseudovirion an HCV glycoprotein, wherein the majority of the glycoprotein is full length. The invention further provides a cell and a pseudovirion expressing such glycoprotein. The invention still further provides a method for determining whether an agent inhibits HCV fusion with and entry into a target cell. The invention also provides an agent that inhibits HCV fusion with and entry into a target cell.
    Type: Grant
    Filed: November 9, 2004
    Date of Patent: April 22, 2008
    Assignees: Albert Einstein College of Medicine of Yeshiva University, Progenics Pharmaceuticals, Inc.
    Inventors: Julie Dumonceaux, Emmanuel G. Cormier, Jason P. Gardner, Tatjana Dragic